-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★The "privatization" of Chinese medicine stocks Sibiman has become the focus, and the potential of the domestic cell therapy market is gradually enlargedYimai New Observation ★"Fengke Interview" Sibiman Stem Cell Division General Manager Dai Chengxiang: talk The current status of clinical transformation of stem cells and Sibiman's experience May 27, 2021/eMedClub News/--The 2021 American Society of Clinical Oncology (ASCO) annual meeting will be online from June 4th to 8th, 2021 Held in the form of a virtual meeting.
The ASCO conference is the world's largest, highest academic, and most authoritative clinical oncology conference.
Many international cutting-edge and much-concerned clinical research results and clinical data will be unveiled at the conference.
As one of the leading cell therapy companies in China, Sibiman Biotechnology will announce the latest clinical data of two potential "Best-in-Class" CAR-T therapies at the ASCO 2021 conference.
In the latest ASCO abstract, it shows good efficacy and safety, which is expected to bring new hope to patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
It is worth mentioning that these two CAR-Ts are produced in a serum-free and completely closed semi-automatic system.
C-CAR039 C-CAR039 is a new type of second-generation bispecific CAR-T, which mainly targets CD19 and CD20 antigens and has the effect of optimizing the bispecific antigen binding domain.
ASCO 2021 abstract published the clinical data of C-CAR039 to evaluate the safety and effectiveness of C-CAR039 in patients with relapsed/refractory B-NHL.
The data showed that 25 patients could be evaluated after administration, the best total effective rate was 92%, the complete remission rate (CR) was 84%, and the median remission time was 1.
0 month; 24 patients (96%) experienced cytokine Releasing Syndrome (CRS), 23 of them were grade 1 or 2 and 1 patient was grade 3.
C-CAR039 has shown good safety and effectiveness in patients with relapsed/refractory B-NHL.
In November 2020, Sibman announced the progress made by C-CAR039 in a trial (IIT) initiated by Chinese Phase I investigators.
The results showed that: C-CAR039 has good tolerability and safety; within 1 month In the efficacy evaluation, 15/16 patients showed complete remission (CR) (87.
5%; 12 DLBCL, 1 FL and 1 tFL) and 1 achieved partial remission (PR).
Twelve patients had follow-up data of 3 months or more.
The overall survival rate (OS) at 3 months was 100%.
The median follow-up time was 156 days (39-345 days), and the median duration of remission (DOR) had not yet been reached.
In addition, the study observed that the expansion of C-CAR039 CAR-T cells in the peripheral blood of patients after treatment was positively correlated with tumor regression.
At present, CD19 CAR-T cell therapy has played a significant response and clinical efficacy in a variety of B-cell malignancies, but there are still non-responses and tumor recurrences, which have aroused wide attention of researchers.
Therefore, researchers have to solve these problems.
, Developed bispecific CAR-T cells.
On the basis of the original CD19 targeting, an additional target can be added to cover more tumor cell subgroups, which can eliminate tumor cells more effectively; at the same time, it can also prevent tumor recurrence caused by the loss of CD19.
It can be said that dual-target CAR-T is a major strategy to solve the non-response and relapse/drug resistance of CAR-T treatment.
According to the data released by the ASCO 2021 abstract, the median follow-up time of C-CAR039 for C-CAR039 of Sibman’s CD19/CD20 CAR-T therapy is 5.
3 months, and the complete remission rate remains at 76%.
This data is very impressive and is expected to bring patients Better clinical benefit.
C-CAR066CAR066 is a CAR-T cell product that targets CD20.
At ASCO 2021, Sibiman announced the Phase 1 clinical data of C-CAR066 to evaluate patients who have received anti-CD19-targeted CAR-T therapy.
r/r Safety and effectiveness in patients with B-NHL.
The results showed that as of the data as of January 31, 2021, a total of 7 patients were enrolled.
At a median follow-up of 7.
8 months, the best response rate was 100%, of which 71.
4% reached a complete response rate (CR), with a median to response rate.
The time was 1.
0 month, and the median time to complete remission was 2.
7 months.
The incidence of CRS was 100% (7/7).
One patient experienced grade 4 CRS and recovered after treatment.
CD20 is a potential target for B-NHL treatment and has been verified in clinical trials.
For CD19 CAR-T in the case of non-response/poor efficacy/tumor recurrence, CD20 CAR-T and CD19 CAR-T can complement each other, as a choice of CD19 CAR-T cell therapy failure or bridging therapy, providing patients with new Treatment options.
Summarizing the two CAR-T cell therapies presented by Sibiman at the ASCO 2021 conference, it mainly supplements and updates CAR-T's work and results in overcoming tumor recurrence and drug resistance.
These two CAR-T cell therapies have also shown positive safety and effectiveness in early clinical studies.
We look forward to more research data in the future, which can bring more clinical benefits to patients. Reference materials: 1.
https://meetinglibrary.
asco.
org/record/196090/abstract2.
https://meetinglibrary.
asco.
org/record/200087/abstractMeetinglibrary has always been committed to cutting-edge technology and industry trends in bio-innovative drugs , Industry Insights and other original news reports, all media high-end matrix users reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups.
The ASCO conference is the world's largest, highest academic, and most authoritative clinical oncology conference.
Many international cutting-edge and much-concerned clinical research results and clinical data will be unveiled at the conference.
As one of the leading cell therapy companies in China, Sibiman Biotechnology will announce the latest clinical data of two potential "Best-in-Class" CAR-T therapies at the ASCO 2021 conference.
In the latest ASCO abstract, it shows good efficacy and safety, which is expected to bring new hope to patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
It is worth mentioning that these two CAR-Ts are produced in a serum-free and completely closed semi-automatic system.
C-CAR039 C-CAR039 is a new type of second-generation bispecific CAR-T, which mainly targets CD19 and CD20 antigens and has the effect of optimizing the bispecific antigen binding domain.
ASCO 2021 abstract published the clinical data of C-CAR039 to evaluate the safety and effectiveness of C-CAR039 in patients with relapsed/refractory B-NHL.
The data showed that 25 patients could be evaluated after administration, the best total effective rate was 92%, the complete remission rate (CR) was 84%, and the median remission time was 1.
0 month; 24 patients (96%) experienced cytokine Releasing Syndrome (CRS), 23 of them were grade 1 or 2 and 1 patient was grade 3.
C-CAR039 has shown good safety and effectiveness in patients with relapsed/refractory B-NHL.
In November 2020, Sibman announced the progress made by C-CAR039 in a trial (IIT) initiated by Chinese Phase I investigators.
The results showed that: C-CAR039 has good tolerability and safety; within 1 month In the efficacy evaluation, 15/16 patients showed complete remission (CR) (87.
5%; 12 DLBCL, 1 FL and 1 tFL) and 1 achieved partial remission (PR).
Twelve patients had follow-up data of 3 months or more.
The overall survival rate (OS) at 3 months was 100%.
The median follow-up time was 156 days (39-345 days), and the median duration of remission (DOR) had not yet been reached.
In addition, the study observed that the expansion of C-CAR039 CAR-T cells in the peripheral blood of patients after treatment was positively correlated with tumor regression.
At present, CD19 CAR-T cell therapy has played a significant response and clinical efficacy in a variety of B-cell malignancies, but there are still non-responses and tumor recurrences, which have aroused wide attention of researchers.
Therefore, researchers have to solve these problems.
, Developed bispecific CAR-T cells.
On the basis of the original CD19 targeting, an additional target can be added to cover more tumor cell subgroups, which can eliminate tumor cells more effectively; at the same time, it can also prevent tumor recurrence caused by the loss of CD19.
It can be said that dual-target CAR-T is a major strategy to solve the non-response and relapse/drug resistance of CAR-T treatment.
According to the data released by the ASCO 2021 abstract, the median follow-up time of C-CAR039 for C-CAR039 of Sibman’s CD19/CD20 CAR-T therapy is 5.
3 months, and the complete remission rate remains at 76%.
This data is very impressive and is expected to bring patients Better clinical benefit.
C-CAR066CAR066 is a CAR-T cell product that targets CD20.
At ASCO 2021, Sibiman announced the Phase 1 clinical data of C-CAR066 to evaluate patients who have received anti-CD19-targeted CAR-T therapy.
r/r Safety and effectiveness in patients with B-NHL.
The results showed that as of the data as of January 31, 2021, a total of 7 patients were enrolled.
At a median follow-up of 7.
8 months, the best response rate was 100%, of which 71.
4% reached a complete response rate (CR), with a median to response rate.
The time was 1.
0 month, and the median time to complete remission was 2.
7 months.
The incidence of CRS was 100% (7/7).
One patient experienced grade 4 CRS and recovered after treatment.
CD20 is a potential target for B-NHL treatment and has been verified in clinical trials.
For CD19 CAR-T in the case of non-response/poor efficacy/tumor recurrence, CD20 CAR-T and CD19 CAR-T can complement each other, as a choice of CD19 CAR-T cell therapy failure or bridging therapy, providing patients with new Treatment options.
Summarizing the two CAR-T cell therapies presented by Sibiman at the ASCO 2021 conference, it mainly supplements and updates CAR-T's work and results in overcoming tumor recurrence and drug resistance.
These two CAR-T cell therapies have also shown positive safety and effectiveness in early clinical studies.
We look forward to more research data in the future, which can bring more clinical benefits to patients. Reference materials: 1.
https://meetinglibrary.
asco.
org/record/196090/abstract2.
https://meetinglibrary.
asco.
org/record/200087/abstractMeetinglibrary has always been committed to cutting-edge technology and industry trends in bio-innovative drugs , Industry Insights and other original news reports, all media high-end matrix users reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups.
